Abstract

Spalt-like proteins are Zinc finger transcription factors from Caenorhabditis elegans to vertebrates, with critical roles in development. In vertebrates, four paralogues have been identified (SALL1-4), and SALL2 is the family’s most dissimilar member. SALL2 is required during brain and eye development. It is downregulated in cancer and acts as a tumor suppressor, promoting cell cycle arrest and cell death. Despite its critical functions, information about SALL2 regulation is scarce. Public data indicate that SALL2 is ubiquitinated and phosphorylated in several residues along the protein, but the mechanisms, biological consequences, and enzymes responsible for these modifications remain unknown. Bioinformatic analyses identified several putative phosphorylation sites for Casein Kinase II (CK2) located within a highly conserved C-terminal PEST degradation motif of SALL2. CK2 is a serine/threonine kinase that promotes cell proliferation and survival and is often hyperactivated in cancer. We demonstrated that CK2 phosphorylates SALL2 residues S763, T778, S802, and S806 and promotes SALL2 degradation by the proteasome. Accordingly, pharmacological inhibition of CK2 with Silmitasertib (CX-4945) restored endogenous SALL2 protein levels in SALL2-deficient breast MDA-MB-231, lung H1299, and colon SW480 cancer cells. Silmitasertib induced a methuosis-like phenotype and cell death in SW480 cells. However, the phenotype was significantly attenuated in CRISPr/Cas9-mediated SALL2 knockout SW480 cells. Similarly, Sall2-deficient tumor organoids were more resistant to Silmitasertib-induced cell death, confirming that SALL2 sensitizes cancer cells to CK2 inhibition. We identified a novel CK2-dependent mechanism for SALL2 regulation and provided new insights into the interplay between these two proteins and their role in cell survival and proliferation.

Details

Title
Casein kinase 2 phosphorylates and induces the SALL2 tumor suppressor degradation in colon cancer cells
Author
Hermosilla, V. E. 1   VIAFID ORCID Logo  ; Gyenis, L. 2 ; Rabalski, A. J. 3 ; Armijo, M. E. 4 ; Sepúlveda, P. 4 ; Duprat, F. 5 ; Benítez-Riquelme, D. 4 ; Fuentes-Villalobos, F. 6 ; Quiroz, A. 4 ; Hepp, M. I. 7 ; Farkas, C. 7 ; Mastel, M. 8 ; González-Chavarría, I. 5 ; Jackstadt, R. 8 ; Litchfield, D. W. 2   VIAFID ORCID Logo  ; Castro, A. F. 4   VIAFID ORCID Logo  ; Pincheira, R. 4   VIAFID ORCID Logo 

 Universidad de Concepción, Departamento de Bioquímica y Biología Molecular, Facultad de Ciencias Biológicas, Concepción, Chile (GRID:grid.5380.e) (ISNI:0000 0001 2298 9663); Universidad de Concepción, Laboratorio de Transducción de Señales y Cáncer, Facultad de Ciencias Biológicas, Concepción, Chile (GRID:grid.5380.e) (ISNI:0000 0001 2298 9663); University of California-San Francisco, Dept of Orofacial Sciences and Dept of Anatomy, San Francisco, USA (GRID:grid.266102.1) (ISNI:0000 0001 2297 6811) 
 University of Western Ontario, Department of Biochemistry, Schulich School of Medicine & Dentistry, London, Canada (GRID:grid.39381.30) (ISNI:0000 0004 1936 8884) 
 University of Western Ontario, Department of Biochemistry, Schulich School of Medicine & Dentistry, London, Canada (GRID:grid.39381.30) (ISNI:0000 0004 1936 8884); Odyssey Therapeutics, Boston, USA (GRID:grid.39381.30) 
 Universidad de Concepción, Departamento de Bioquímica y Biología Molecular, Facultad de Ciencias Biológicas, Concepción, Chile (GRID:grid.5380.e) (ISNI:0000 0001 2298 9663); Universidad de Concepción, Laboratorio de Transducción de Señales y Cáncer, Facultad de Ciencias Biológicas, Concepción, Chile (GRID:grid.5380.e) (ISNI:0000 0001 2298 9663) 
 Universidad de Concepción, Departamento de Fisiopatología, Facultad de Ciencias Biológicas, Concepción, Chile (GRID:grid.5380.e) (ISNI:0000 0001 2298 9663) 
 Universidad de Concepción, Departamento de Bioquímica y Biología Molecular, Facultad de Ciencias Biológicas, Concepción, Chile (GRID:grid.5380.e) (ISNI:0000 0001 2298 9663); Universidad de Concepción, Laboratorio de Transducción de Señales y Cáncer, Facultad de Ciencias Biológicas, Concepción, Chile (GRID:grid.5380.e) (ISNI:0000 0001 2298 9663); Universidad de Concepción, Laboratorio de Inmunovirología. Departamento de Microbiologia. Facultad de Ciencias Biológicas, Concepción, Chile (GRID:grid.5380.e) (ISNI:0000 0001 2298 9663) 
 Universidad de Concepción, Departamento de Bioquímica y Biología Molecular, Facultad de Ciencias Biológicas, Concepción, Chile (GRID:grid.5380.e) (ISNI:0000 0001 2298 9663); Universidad de Concepción, Laboratorio de Transducción de Señales y Cáncer, Facultad de Ciencias Biológicas, Concepción, Chile (GRID:grid.5380.e) (ISNI:0000 0001 2298 9663); Universidad Católica de la Santísima Concepción, Laboratorio de Investigación en Ciencias Biomédicas, Departamento de Ciencias Básicas y Morfología, Facultad de Medicina, Concepción, Chile (GRID:grid.412876.e) (ISNI:0000 0001 2199 9982) 
 German Cancer Research Center (DKFZ) and DKFZ-ZMBH Alliance, Heidelberg Institute for Stem Cell Technology and Experimental Medicine (HI-STEM gGmbH), 69120 Heidelberg. Cancer Progression and Metastasis Group, Heidelberg, Germany (GRID:grid.482664.a); Heidelberg University, Faculty of Biosciences, Heidelberg, Germany (GRID:grid.7700.0) (ISNI:0000 0001 2190 4373) 
Pages
223
Publication year
2024
Publication date
Mar 2024
Publisher
Springer Nature B.V.
e-ISSN
20414889
Source type
Scholarly Journal
Language of publication
English
ProQuest document ID
2957802659
Copyright
© The Author(s) 2024. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.